Cancer therapy: know your enemy? by Mike-Andrew Westhoff et al.
Westhoff et al. Molecular and Cellular Pediatrics 2014, 1:10
http://www.molcellped.com/content/1/1/10MINI REVIEW Open AccessCancer therapy: know your enemy?
Mike-Andrew Westhoff1*, Oliver Brühl2 and Klaus-Michael Debatin1*Abstract
Background: Most cancer therapies are devised for adult or even elder patients. However, when dealing with
pediatric cancers, additional considerations are needed.
Conclusions: This review discusses non-classic components of tumors and highlights possible treatment
approaches which might be of particular benefit for children and adolescents.
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Cancer is still foremost to be considered a disease of old
age, generally occurring after a lifetime of accumulated
insults to our DNA's integrity which finally overcome the
body's repair and control mechanisms; indeed, over a third
of all cancer cases occur in members of the population
who are 75 years of age or older, while less than 1% can be
found in children and adolescents [1]. This, in turn, means
that most therapies have been developed and optimized
towards adult and elderly patients in particular and that
most data on efficacy and long-term effects are also
derived from these populations.
A distinct set of problems and deliberations has to be
considered when designing novel treatment strategies
in pediatric oncology. Foremost among those are the
long-term adverse effects of treatment, which might
only occur decades after the initial disease has been
successfully treated, these include among others peri-
pheral neurotoxicity [2], cardiovascular disease, and
second malignant neoplasms [3]. For example, already
1 year after radiotherapy, the risk of acute leukemia
and non-Hodgkin lymphoma is increased in patients
with solid tumors [4]. So far, comprehensive studies
addressing these issues are sadly lacking. In addition,
there are rather acute effects of treatment that can
severely affect a child's quality of life, and among these
can be treatment-induced loss of hearing, fatigue and
weakness, increased susceptibility to infection, and growth* Correspondence: andrew.westhoff@uniklinik-ulm.de; klaus-michael.debatin@
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in any medium, provided the original work is pretardation. Current treatment options often appear harsh
and even morbid to young patients and their parents.
There are several recent cases where the patients and/or
their guardian have opted out of a successful treatment
plan and sought ‘alternative’ options, often with un-
fortunate consequencesa. Finally, while an unsurpassed
success over the last 30 years has been achieved in the
therapy for childhood leukemias, pediatric cancer is the
most common cause of death in children (aged 1 to 14
years) and among the four most common forms of
deaths in teenagers and young adults (aged 14 to 25) [1].
Therefore, novel therapeutic approaches, taking into
account the specific difficulties regarding the treatment of
children and young adolescents, are clearly needed.
While we argue elsewhere that chronification of the ma-
lignancy can be a valid approach in older or elderly cancer
patients [5], especially since the long-term effects of treat-
ment, which might only manifest several decades later, do
not need to be taken into account, we do not have this
luxury when dealing with children or adolescents. Here,
both the long-term impact on the patient's health from
excessive treatment toxicity, as well as the totality of life
lost if a too weak chemo- or radiotherapy is selected must
be taken into account. Therefore, increased treatment spe-
cificity for the whole of the cancerous cell population,
while concurrently minimizing the collateral damage to
healthy tissue, is the paramount challenge when devising
novel treatment options for young patients.
The first question for this strategy to succeed that needs
to be answered seems almost trivial, however, the last
decade or so has demonstrated time and time again that
our textbook knowledge is far from complete. This ques-
tion is: What is the sum total of the tumor?s an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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The modern view of what constitutes cancer evolved over
the last 60-odd years, beginning in 1953 with the multiple-
hit hypothesis, which led to the identification of oncogenes
and proto-oncogenes in the 1970s and the subsequent
development of the cancer progression, or multistep
carcinogenesis, model in 1990 [6]: an individual cell, or
a small population of cells, accumulates an increasing
amount of mutations over time, which leads to un-
controlled growth, an ever increasing independence
from the surroundings and finally, the ability to avoid
death signals and to metastasize - the so-called hall-
marks of cancer [7]. This model suggests that the
phenotype of a cancer is due to a combination of essential
driver mutations, those which make tumor progression
possible, and random passenger mutations. If a mutation
occurs, either due to the inherent genetic instability of
cancer cells or provoked by treatment, that gives a cancer
cell a growth advantage for the present fitness landscape
that leads to a clonal expansion of this subpopulation [5].
The cancer stem cell (CSC) model, which, although
proposed in 1937, only gained traction in the 1990s [6],
adds another layer of complexity. These mechanisms are
still valid for the cancer cell of origin, which can - but
need not be - identical to the CSC. The CSC hypothesis
postulates the existence of a stem cell niche within the
tumor where a cell population resides that has acquired
properties associated with normal stem cells, such as self-
renewal and differentiation into multiple cell types found
within the tumor. CSC make up only a fraction of a
percent of total tumor bulk, and due to the high plasticity
of their phenotype and their ability to remain quiescent
for probably many decades, they are held responsible for
relapse and therapy failure [6,7].
In essence, the prevalent, but incomplete, view is of
cancer as a genetic disease caused by the accumulation of
mutations. Therefore, using tools and models provided by
the fields of (population) genetics and ecology, the failure
to treat a cancer successfully over a prolonged period of
time can best be understood as our failure successfully to
compete in the Red Queen arms raceb: because of the
genetic instability inherent in cancer cells, we are targeting
a rapidly changing collective of populations that quickly
adapt to changes in the fitness landscape with a mech-
anistically very limited arsenal of tools. In essence, both
radio- and the majority of chemotherapy function by
either directly or indirectly inducing DNA damage and,
therefore, to a mutational change within the cancer cell
that allows propagation despite compromised DNA integ-
rity. This could cause, for example, the deactivation of cell
cycle checkpoints or enhanced exclusion of therapeutic
reagents or increased expression of multidrug-resistance
proteins, leading, as the name of the latter example
already suggests, to resistance not only against alreadyused therapeutic avenues but also against possible future
approaches. So far, frequently, the only available response
to emerging resistance has been the increase in ‘firepower’,
i.e., enhanced doses of the therapeutics. Taking our cues
from the field of population genetics, two possible
approaches can be identified that might help to treat the
patients more successfully, i.e., keep up in the arms race.
One, increase the arsenal at our disposal to include treat-
ment options which kill the cancer cells not by direct
DNA damage, but alternative routes, for example, trigger-
ing of death receptors via synthetic ligands or antibodies
[8]. Two, change the target to something that, taking up
the Red Queen metaphor, runs more slowly, i.e., target a
genetically more stable component of the tumor, for
example, the tumor microenvironment (TME) or the
interface between mutated cancer cell and TME. Here, we
will focus on this latter aspect.
The tumor microenvironment
In 1889, Paget suggested in what has become known as
soil-and-seed hypothesis that a cancer cell thrives wher-
ever it encounters a permissive environment, thus explain-
ing the preferred sites of metastasis [6]. While the ensuing
research has focused mainly on the seed, i.e., the mutated
cancer cell, emerging evidence suggests that the soil, i.e.,
the microenvironment, far from being a randomly en-
countered niche during metastasis, is, already at the site of
the primary tumor, a specialized tissue that should be
viewed as an integral part of the tumor [7]. While the gen-
eral focus when dealing with the TME lies on the tumor-
associated stroma cells, it is composed of not only cells,
such as fibroblasts, epithelial and endothelial cells,
macrophages, and leukocytes, but also components of
the extracellular matrix, such as collagen and fibro-
nectin [9]. Mutated cells communicate with these com-
ponents via heterotypic cell-cell interaction, in the case
of other cells, or via cell-substrate interaction, when
dealing with components of the extracellular matrix [5].
These interactions are not only essential for the three-
dimensional organization of the tumor, including but
by no means limited to vascularization, they also medi-
ate a phenomenon called AMAR, or adhesion-mediated
apoptosis resistance [5]: cancer cells which are in
contact with their microenvironment show increased
resistance towards both radio- and chemotherapy,
which induce apoptosis, a form of cell suicide. This is
mediated by enhanced survival signaling or a reduction
of the death signaling and, importantly, specifically
blocking these interactions can in turn sensitize the
mutated cells for apoptosis, even if the cell and its TME
are not physically removed from each other [5]. Therefore,
inhibiting the interaction between mutated cell and TME,
in essence, blinding the cancer cell to its surroundings,
leads to a reduction in therapeutic intervention needed,
Figure 1 (See legend on next page.)
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Figure 1 Tumor composition. Generalized schematic representation of a tumor, showing both components that make up the malignancy:
Mutated tumor cells, both putative tumor stem cells in their niche (11) and various differentiated subclonal populations (5), which can be in direct
competition (8). The microenvironment, composed of newly formed (2) and forming (6) blood vessels, components of the extracellular matrix, such
as fibronectin (9), normal surrounding tissue, and cells altered by their proximity to the mutated tumor cells, including fibroblasts (13). Of note, the
highly motile TAMs (7), which do not penetrate the malignancy deeply, but at the tumor periphery can either facilitate tumor growth and invasion
or enhance the chemotoxic effects of therapy. Several forms of interaction between mutated tumor cell and microenvironment are also shown, such
as the destruction of the microenvironment during invasion (12), the co-opting of blood vessels to increase dissemination (10), and the creation of a
novel microenvironment during invasion (1), establishing a premetastatic niche prior to its colonization by cancer cells (3) and the possible formation
of distant metastasis by de-differentiation (4). This view of cancer leads to additional potential therapeutic avenues to pursue [5], such as the possibility
of blocking the tethering points between cancer cell and matrix and the communication between mutated cancer cells and tumor-associated cells,
which can lead to reversion of the tumor microenvironment to ‘normal’ tissue that does not necessarily support tumor growth and either death of
the tumor cell by a specialized form of cell death (anoikis) (14) or at least its sensitization towards conventional therapy, i.e., the inhibition of AMAR.
Importantly, therapeutic targets must be carefully chosen, as not to enhance cell motility and thereby increase potential invasion/metastasis.
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more, increased isolation from the cancer niche might
even lead to anoikic cell death, the cancer cells dying with-
out the need of additional therapeutic intervention [5]. It
has even been suggested that the development of the
TME occurs concurrently and is essential for the multi-
step carcinogenesis [10] and there is compelling
evidence for the formation of a premetastatic niche
prior to the establishment of a colony of mutated
cancer cells, i.e., the soil is fertilized prior to the seed
growth [11]. Therapeutically, reestablishing the ‘normal’
unaltered microenvironment can be sufficient to block
tumor progression and tumor formation [12,13]. In
addition, far from being a hindrance during local invasion
and metastasis, which needs to be broken down in order
for the cancer cell to progress to distant sites, several
components of the TME actively cooperate with tumor
cells in these processes [9]. Our own recent work suggests
that by inhibiting the interaction between cancer cell and
TME - in particular, Fibronectin, which was predomin-
ately produced by those cells at the leading invasive edge
of the tumor, inhibits their migratory capacity - metastasis
can be blocked (summarized in [5]). However, depending
on the target, the opposite can occur, blocking desmo-
somes, tethering point for intermediate filaments, or tight
junctions, at the boundary between apical and basal
domains of the plasma membrane, within the tumor can
actually increase invasion [5].
The complexity of the TME's role has been further
highlighted in recent research into the role of macro-
phages within the tumor. These cells, which are phago-
cytes involved in both innate and adaptive immunity,
make up a rather mobile component of the TME. They
are attracted to hypoxic and necrotic areas of the tumor
and are believed to mediate chronic inflammation, apop-
tosis resistance, and neovascularization, i.e., to ensure
tumor survival and propagation. Tumor-associated mac-
rophages (TAMs) can often not penetrate the tumor
growth due to the altered metabolism of the cancer cell,
which, in essence, creates a too toxic environment forTAMs to thrive [14]. Basically, the same signals which
attract TAMs to the tumor prevent them from reaching
the majority of cancer cells. This seems rather counter-
intuitive if TAMs are recruited to the tumor to facilitate
oxygen supply and, thus, metabolic alterations and
survival of the tumor. However, if one considers the role
of macrophages in the body's immune response, a rather
intriguing possibility emerges: while the TAMs can be
co-opted by the cancer cells at the tumor periphery to
mediate invasion, they need to be kept out of the actual
growth, as they might exert an anti-tumorigenic effect
there. Several new studies seem to confirm that, both a
healthy bacterial flora to activate the immune system
and macro-phages to execute the immune response are
needed for chemotherapeutic intervention to be fully
successful [15-17]. Interestingly, therapeutically altering
the TME to enhance the macrophage response also
seems practical in non-solid cancers, such as leukemia
[15].
A frequently voiced objection to targeting the TME is
that it provides a far less comfortable therapeutic
window, i.e., the view that non-mutated cells within a
cancer are patient cells and therefore targeting those
cells will lead to increased damage of healthy tissue.
While correct on a strictly genetic level, this caveat
does not take into account the dynamic reciprocity that
exists between the different components of the tumor.
In essence, not only does the TME provide the mutated
cell with a niche in which to survive, but the cancer cell
also alters the TME, giving it a distinct phenotype and indi-
vidual epigenetic signature [9,18]. Importantly, unlike
mutated cancer cells, cells from TME readily revert to their
non-disease associated phenotype, while providing a slower
proliferating, genetically more stable target for thera-
peutic interventions compared to cancer cells [18].
Therefore, blocking the influence of the cancer cells on
the TME and of the TME on the cancer cells, in
essence, either targeting the soil or the seed's ability to
interact with it, should lead to a more localized disease
and can be sufficient to kill cancer cells, either by needing
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the need of any further radio- or chemotherapy.
Conclusions
While pediatric cancers are a relatively rare form of this
malignancy, they are among the leading causes of death
in children and adolescents. When considering quantity
of life lost in years, it is difficult to imagine a more
deadly disease. However, most therapeutic approaches
are devised focusing adult or even elderly patients, thus
often not considering the long-term burden on the pa-
tients' health. Most therapies are based on the maximum
dose density of the Norton-Simon model, which postu-
lates maximal killing of tumor cells by using therapeutic
doses close to, or in extreme cases exceeding the limit of
tolerable [19]. This approach, if not instantaneously
successful, leads to an arms race that frequently ends with
the emergence of a therapy-resistant tumor. On the other
end of the spectrum is the adaptive therapy approach,
which postulates a chronification of the disease [19], while
we favor this approach in general [5], it is not feasible
when treating pediatric cancers. A third option, metro-
nomic therapy which postulates continuous treatment
with lower therapeutic doses, might have less severe long-
term side effects, but is not designed to prevent emer-
gence of resistance [19].
To devise new, successful treatment options for pediatric
cancer, we postulate going back to the stratagem first
suggested by the Chinese strategist Sun-Tzu more than
2,000 years ago: The success in a campaign can be greatly
enhanced, if one knows not only oneself but also one's
opponent. In the case of cancer, we have just begun to
address the latter aspect. By understanding cancer not just
as a population of mutated cells but as a complex eco-
system consisting of mutated cells, non-mutated but
epigenetically altered cells, unaltered cells and extra-
cellular components, new modes of intervention can
become apparent (Figure 1). For example, isolating the
mutated cancer cell from it's surrounding, either by
targeting the TME or the cells' interaction with the
TME leads to three distinct therapeutic benefits.
1) AMAR is reduced, i.e., lower doses of therapeutic
reagents are needed to kill the same amount of
cancer cells; therefore, side effects and risks of
secondary cancers are reduced. Ideally, this
reduction leads to…
2) Total isolation of cancer cells from their TME and
each other (sometimes rather whimsically referred
to as Alcatraz approach), which can lead to anoikis,
i.e., the death of tumor cells without additional
therapeutic intervention. Even if these points are not
fully achieved, they can still contribute significantly
to…3) Reduced invasion and metastasis. The interaction
between tumor cell and TME is essential for the
spread of cancer. Even if mutated cancer cells do
not die via this intervention, cancer still potentially
becomes a more localized disease. This in turn
opens additional therapeutic options to be pursued.
The role of the TME is far from being fully under-
stood, and further research is clearly needed, as seen for
example, when discussing the TAMs. Here, the complex
interaction between bacteria, immune system, and ther-
apy clearly indicates that individual components of the
TME can have diverse, apparently contradictory func-
tions. Importantly, understanding these interactions has
direct implications for patient care. In this particular
case, the routine administration of antibiotics in im-
munocompromised cancer patients, while avoiding po-
tential infections, reduces the efficacy of chemotherapy.
Footnotes
aExamples, such as the cases of Daniel Hauser or Sarah
Hershberger, are discussed by surgical oncologist David
H. Gorski at www.sciencebasedmedicine.org.
bThe Red Queen hypothesis postulates antagonistic
coevolution between competing populations (either of
the same species or of distinct species, e.g., predator/prey
or host/parasite). For the relationship between those
populations to remain in equilibrium, both have to
constantly adapt and evolve in an unstable environment.
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